For a Chinese plasma product, import into India is two questions. First, whether China will export it — covered in the export regulations and market-entry guide. Second, whether India will register and admit it. This page is about the second question.
The regulator and the law
The Central Drugs Standard Control Organisation (CDSCO), under the Directorate General of Health Services and the Ministry of Health and Family Welfare, regulates drugs, biologicals and vaccines under the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. Imported biological products are further governed by the New Drugs and Clinical Trials (NDCT) Rules, 2019.
One point matters more than the rest: under the NDCT Rules, 2019, specified biological products are always deemed to be new drugs. This means a plasma-derived product or vaccine cannot go straight to import licensing — the new drug permission must be obtained first, even when the product is long-established in its home market.
The three authorisations, in order
An Indian import of a biological product runs through three distinct stages. They are sequential and often confused:
| Stage | Form | What it is | Who holds it |
|---|---|---|---|
| 1. New drug permission | CT-20 (formulation) / CT-19 (API) | CDSCO permission to import the biological as a new drug | The Indian applicant |
| 2. Registration Certificate | Form 41 | Registration of the foreign site and product | Filed by the authorised Indian agent |
| 3. Import Licence | Form 10 | The licence to actually bring the product in | The licensed Indian importer |
The key constraint: a Chinese company cannot hold the Indian registration. The foreign manufacturer must appoint an authorised Indian agent holding a wholesale drug licence (Form 20B or 21B), and that agent files the application on the CDSCO SUGAM portal. What the exporter contributes is the product file; what the Indian agent contributes is the licence and the filing.
The dossier the Chinese side must supply
The core file a Chinese exporter must supply is the same one described in the general market-entry guide, plus the documents India authenticates through its embassy:
- Certificate of Pharmaceutical Product — the WHO-format status evidence, authenticated by the Indian embassy.
- The drug approval number, verifiable on the NMPA database.
- The batch release certificate — that the specific lot was state-released.
- GMP evidence for the manufacturing site, from the Chinese authority.
- The product dossier — specifications, analytical methods, stability data, packaging details.
- A Plant Master File and a notarised Form 9 manufacturer's undertaking, authenticated by the Indian embassy.
Where available, a WHO prequalification certificate materially shortens the review. Registration and import licences are each valid for three years, and a facility inspection may be required at the applicant's cost.
The sequence, end to end
| Step | What happens | Who does it |
|---|---|---|
| 1. Confirm exportability | Product is finished, registered, batch-released — not source plasma | Exporter + manufacturer |
| 2. Appoint the Indian agent | An authorised agent with a Form 20B/21B wholesale licence | Importer side |
| 3. New drug permission | File for CT-20 (or CT-19) on the SUGAM portal | Indian applicant |
| 4. Register site + product | Form 40 application → Form 41 Registration Certificate | Authorised Indian agent |
| 5. Import licence | Form 8 application → Form 10 Import Licence | Licensed importer |
| 6. Ship & clear | Upload registration + licence to e-Sanchit, clear through customs | Licensed importer + CDSCO |
At the bill-of-entry stage, both the registration certificate and the import licence must be current and uploaded to e-Sanchit before customs will grant out-of-charge. A licence that has lapsed, or a registration that covers a different formulation, will hold the consignment.
How a Chinese export agent fits in
Wanyoda's role is the export side of this sequence. We hold the written export mandates from NMPA-licensed manufacturers and coordinate the product file — approval number verification, CPP, batch release and GMP evidence — so the Indian agent receives a complete, filing-ready dossier. We do not hold the Indian registration, because by law it is filed through an authorised Indian agent.
What this means in practice: the fastest Indian entry is one where the export-side product file is already complete and the Indian agent already holds its wholesale licence and new drug pathway. Registration then becomes adaptation and filing rather than a long evidence-gathering exercise.
The Indian constraint that matters most: biologicals are new drugs, so the new drug permission comes before the import licence. Plan the CT-20 step first — it is the one most first-time importers discover late.
Frequently asked questions
What authorisation is required to import a blood product into India?
A Registration Certificate in Form 41 from CDSCO for the foreign manufacturing site and product, followed by an Import Licence in Form 10 held by a licensed Indian importer. Biological products are treated as new drugs, so permission under CT-19/CT-20 is also required before the import licence.
Can a Chinese company hold the Indian registration?
No. Foreign manufacturers apply through an authorised Indian agent holding a wholesale drug licence (Form 20B/21B). The agent files Form 40 on the SUGAM portal; the Chinese exporter supplies the product file.
How long is a CDSCO Form 41 registration valid?
A Form 41 Registration Certificate and a Form 10 Import Licence are each valid for three years from the date of issue.
What documents does the Indian application require from the Chinese side?
A Certificate of Pharmaceutical Product (CPP) from the NMPA, a GMP certificate, the product dossier with specifications and stability data, a Plant Master File, and a notarised Form 9 manufacturer's undertaking, authenticated by the Indian embassy.
Where to go next
- The destination-by-destination guide — how India compares to the Philippines and other markets.
- Export to the Middle East — the SFDA and GCC batch-by-batch regime, for comparison.
- The Philippines market page — the dedicated landing page for the Philippine channel and its registration status.
- Certificate of Pharmaceutical Product — the document every dossier turns on.
- Batch release: what actually gates a shipment — why the manufacturer cannot release its own product.
- Open territories — where we are actively appointing partners.